Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

This is triggered by liver cirrhosis — when scar tissue builds up in the organ, usually as a result of heavy drinking, obesity or the viral infection hepatitis. The new findings back up research ...

Despite being the largest internal organ and a vital powerhouse of the body, the liver’s health is often overlooked. Dr.

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

Introduction Liver cirrhosis and other chronic liver diseases is a serious public health problem, and its incidence, morbidity, and mortality have increased in recent years (1). In 2019, 1691.0 ...

A report into the timeliness of compensation for those infected and affected is due to be published on Wednesday, following ...